GlassScriptPhysician profile
Stormi Raines
NPI 1558880872
$2,775.11
in general payments reported to CMS, 2019-2025
26 companies · $723 in 2025
The $723 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $550 · 2023: $807 · 2024: $564 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $491.00 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $408.82 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Novo Nordisk INC | $361.34 | 2021-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $340.50 | 2021-2025 | |
| Lilly USA, LLC | $226.63 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.83 | 2023-2025 | Jardiance, Tradjenta |
| Mylan Specialty L.P. | $117.30 | 2023-2024 | Yupelri |
| Organon LLC | $87.74 | 2023 | Nexplanon |
| Glaxosmithkline, LLC. | $79.36 | 2021-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $75.17 | 2022 | |
| Amarin Pharma, INC. | $50.30 | 2021-2022 | |
| Amgen INC. | $47.91 | 2025 | Evenity, Repatha, Otezla |
| Axsome Therapeutics, INC. | $40.33 | 2025 | Sunosi |
| Bayer Healthcare Pharmaceuticals INC. | $37.33 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $37.17 | 2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $32.58 | 2024 | Nexletol |
| Exact Sciences Corporation | $28.86 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $26.62 | 2022 | |
| Corcept Therapeutics | $21.74 | 2022 | |
| Viatris Specialty LLC | $20.70 | 2025 | Yupelri |
| Abbvie INC. | $19.87 | 2024 | |
| Verona Pharma, INC. | $19.66 | 2025 | Ohtuvayre |
| Dexcom, INC. | $19.61 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $14.04 | 2024 | Voquezna |
| Avanir Pharmaceuticals, INC. | $11.98 | 2022 | |
| Athena Bioscience, LLC | $10.72 | 2023 | Qdolo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stormi Raines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.